NCT02181023View on ClinicalTrials.gov

Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

October 31, 2014

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Aclidinium Bromide

Aclidinium Bromide 322 mcg inhalation powder via Genuair inhaler (Eklira) Product by Almirall, S.A. Ronda General Mitre, 151. ES-08022 Barcelona, Spain

DRUG

Glycopyrronium Bromide

Glycopyrronium Bromide 44 mcg dry powder (capsules) inhaled via Breezehaler inhaler, Seebri - product by Novartis Europharm Limited - Wimblehurst Road, Horsham, West Sussex, RH12 5AB; United Kingdom

Trial Locations (1)

20142

Fondazione Salvatore Maugeri, Milan

All Listed Sponsors
collaborator

Fondazione Salvatore Maugeri

OTHER

lead

University of Milan

OTHER

NCT02181023 - Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients | Biotech Hunter | Biotech Hunter